IKT
Inhibikase Therapeutics
IKT56
$1.79arrow_drop_down2.17%-$0.04
Penny Stock
IKT
IKT56
$1.79
arrow_drop_down2.17%Performance History
| Key Stats | |
|---|---|
| Open | $1.82 |
| Prev. Close | $1.84 |
| EPS | -3.12 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $150.91M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 1.75 | 1.96 |
| 52 Week Range | 0.79 | 4.24 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | -3.12 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Inhibikase Therapeutics (IKT)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Milton H. Werner Ph.D.
- Headquarters
- Atlanta
- Employees
- 6
- Exchange
- NASDAQ
Keep an eye on Inhibikase Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Inhibikase Therapeutics 's (IKT) price per share?
The current price per share for Inhibikase Therapeutics (IKT) is $1.79. The stock has seen a price change of -$0.04 recently, indicating a -2.17% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Inhibikase Therapeutics (IKT)?
For Inhibikase Therapeutics (IKT), the 52-week high is $4.24, which is 136.21% from the current price. The 52-week low is $0.79, the current price is 127.22% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Inhibikase Therapeutics (IKT) a growth stock?
Inhibikase Therapeutics (IKT) has shown an average price growth of -1.65% over the past three years. It has received a score of 17 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Inhibikase Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Inhibikase Therapeutics (IKT) stock price performance year to date (YTD)?
As of the latest data, Inhibikase Therapeutics (IKT) has a year-to-date price change of -44.77%. Over the past month, the stock has experienced a price change of -8.42%. Over the last three months, the change has been -27.62%. Over the past six months, the figure is -22.29%.
help
Is Inhibikase Therapeutics (IKT) a profitable company?
Inhibikase Therapeutics (IKT) has a net income of -$19.03M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -100M% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$20.09M. Furthermore, the EBITDA is -$20.04M.
help
What is the market capitalization of Inhibikase Therapeutics (IKT)?
Inhibikase Therapeutics (IKT) has a market capitalization of $150.91M. The average daily trading volume is 1.82, indicating the stock's liquidity and investor engagement.